RecruitingACTRN12625000121460

A Physician-Pharmacist Partnership Intervention for Deprescribing (P3iD) among Older Adults Attending a Falls and Syncope Clinic: Protocol for a Randomised Controlled Trial

Effect of A Physician-Pharmacist Partnership Intervention for Deprescribing (P3iD) on Total Number of Prescribed Medications among Older Adults Attending a Falls and Syncope Clinic: Protocol for a Randomised Controlled Trial


Sponsor

Universiti Malaya-Department of Medicine Research Support Fund, Faculty of Medicine

Enrollment

140 participants

Start Date

Dec 3, 2024

Study Type

Interventional

Conditions

Summary

Our study aimed to assess the effectiveness of the Physician-Pharmacist Partnership Intervention for Deprescribing (P3ID) among older persons attending a falls and syncope clinic. This randomised controlled trial will be conducted at a teaching hospital in Kuala Lumpur, Malaysia. Participants will involve individuals aged 60 years and over with multiple chronic diseases, prescribed oen or more medications with one or more potentially inappropriate medication (PIM) and attending physicians at the clinic. The joint pharmacist-physician intervention comprises five steps: 1) PIM identification, 2) decision on cessation and prioritisation, 3) medication withdrawal, 4) monitoring and support, 5) and documentation.


Eligibility

Sex: Both males and femalesMin Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

As we get older, we often end up taking many different medications for multiple health conditions. Some of these medicines may no longer be necessary or may even increase the risk of falls. This study is testing a team approach — where a pharmacist and doctor work together — to safely reduce or stop unnecessary medications in older adults who attend a falls and balance clinic. The program involves five steps: identifying potentially risky medications, deciding which ones to stop first, carefully withdrawing them, monitoring the person closely, and documenting everything. The goal is to reduce the burden of medicines while keeping people healthy and reducing their risk of falling. The study is being conducted at a teaching hospital in Kuala Lumpur, Malaysia. If you are 60 years or older, have at least one long-term health condition requiring medication, and attend the falls and syncope clinic, you may be eligible. There are no strict exclusion criteria for patients, though your doctor's participation in the study is also required. This study is about helping older adults live more safely with fewer, better-targeted medications.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Participants in the intervention group will receive an in-depth medication review of approximately 30 minutes performed by a pharmacist, which will focus on identifying PIMs as opportunities for depre

Participants in the intervention group will receive an in-depth medication review of approximately 30 minutes performed by a pharmacist, which will focus on identifying PIMs as opportunities for deprescribing. In the intervention group, PIMs identified will be deprescribed using the P3ID intervention. P3ID intervention consists of 5 steps: Step 1: PIM identification a) Participant selection Researcher reviews electronic medical record (EMR) before follow-up to obtain medication list and identify any potentially inappropriate medications (PIMs). The researcher will then contact selected potential participants, asking them to arrive an hour before their scheduled appointment at the clinic and reminding them to bring their medications for review. b) Medication review The participant completes the written consent form and a baseline demographic questionnaire, Patients were then asked to complete the Patient Medication Adherence Instrument (PMAI-9), a self-reported measure designed to assess medication adherence from the patient's perspective. The pharmacist conducts a medication review using the STOPPFall criteria to identify PIMs and asks about any medication-related issues and self-monitoring practices (e.g., blood pressure or glucose levels). The pharmacist then completes the Healthcare professional-Medication Adherence Instrument (HMAI-9), a self-reported tool designed to evaluate medication adherence from the healthcare professional's perspective. Step 2: Decisions on prioritization on cessation Algorithm for deciding order and mode in which drug use could be discontinued will be applied to determine deprescribing strategy. Step 3: Medication withdrawal a) Physician-pharmacist discussion Pharmacist discusses deprescribing opportunities with physician. b) Doctor-patient consultation If physicians decides to deprescribe, discussion is held with patients Step 4: Monitoring and support a) Doctor’s feedback to the pharmacist Physician will inform the pharmacist of patients’ latest medication regimen b) Medication counselling Pharmacist counsel patients and reinforce instructions given by physician. Step 5: Documentation Physician documents consultation and shared decision at EMR


Locations(1)

Malaysia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12625000121460